Friends for Life® - Orlando 2019 - Sponsors
Platinum Level Sponsors
Ever since we introduced the first commercial insulin in 1923, Lilly Diabetes has been a global leader in diabetes care. Today, Lilly continues to develop innovative products, programs, and resources to help people with type 1 diabetes. For more than a decade, Lilly has been a proud platinum sponsor of the Friends for Life® conference.
Join us to see all the ways we support the type 1 community and how your family can get involved with all the programs Lilly Diabetes supports. We have redesigned our booth this year to include more interactive experiences for all ages. Being at Friends For Life is a fun, learning experience. Come share some time with us in the Lilly Diabetes booth.
Find out how Lilly Diabetes can help your family at LillyDiabetes.com. Take a look at Coco’s adventures and learn from other families with type 1 diabetes at T1EverydayMagic.com. Follow us on social media: Facebook: T1EverydayMagic, Lilly Diabetes. Twitter: @LillyDiabetes. Instagram: T1EverydayMagic.
In 1923, the founders of Novo Nordisk began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is proud to once again be a Platinum Level Sponsor of the Friends for Life conference, supporting the Family and Friends Banquet and Sports Central. Please come see us at the exhibition to learn more about our type 1 support program, our new camp program and be among the first to learn about the first and only durable insulin pen with 0.5 unit doing and memory function – NovoPen Echo®. To learn more about Novo Nordisk and our support to the type 1 diabetes community visit us at www.novonordisk-us.com.
Gold Level Sponsors
Dexcom, Inc., headquartered in San Diego, CA, is dedicated to developing innovative glucose sensing technology and products to help patients and healthcare providers better manage diabetes. The Dexcom G6™ Continuous Glucose Monitoring (CGM) System does not require fingersticks for calibration or diabetes treatment decisions* and features simple, one-touch sensor insertion. The System provides exceptional accuracy with an overall MARD of 9.0%† and features an Urgent Low Soon alert that can warn users 20 minutes in advance of severe hypoglycemia (55 mg/dL). Dexcom is the only provider of CGM systems indicated for children ages 2 years and older. Please visit www.dexcom.com.
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†MARD is a statistical measure of accuracy; the lower the number, the better.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s Omnipod DASH System was designed to serve as the foundation for the Company’s future innovation. Designed with patient discretion and convenience in mind, the Omnipod DASH is a continuous insulin delivery system consisting of two simple components: a tubeless, waterproof, bluetooth® wireless technology Pod (pump) that holds up to 200 units of U-100 insulin and a modern, color touch-screen Personal Diabetes Manager (PDM) that controls the Pod. Coming in summer 2019, the Omnipod DASH System will have a suite of optional mobile apps for users, caregivers and HCPs to help simplify diabetes management. The Omnipod DASH System, which received FDA clearance in June 2018, is the only DTSec and ISO 27001 certified insulin pump for cyber and information security and safety.
Silver Level Sponsors
Abbott Diabetes Care, a division of global health care company Abbott, is committed to improving the lives of people with diabetes. The company manufactures, distributes and markets innovative glucose monitoring systems and others valuable services to help patients and healthcare professionals better manage diabetes care needs. Abbott Diabetes Care is pleased to be a sponsor of Friends for Life Orlando Conference. For more information, visit www.abbottdiabetescare.com.
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2™ Insulin Pump, the only pump capable of remote feature updates using a personal computer, and the t:flex® Insulin Pump, the first pump designed for people with greater insulin requirements. Tandem is based in San Diego, California.
Bronze Level Sponsors
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care, and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services, and devices. Sanofi markets medications for people with type 1 or type 2 diabetes. To follow conversations about life, and life with diabetes connect with us and register for diabetes related articles and lifestyle tips on The DX, like us on Facebook at Sanofi US Diabetes and follow us on Twitter at @diabetes_sanofi.
Xeris Pharmaceuticals, Inc., headquartered in Chicago, IL, is dedicated to unlocking the potential of glucagon. The company believes that easier-to-use medicines can have a profound impact on the lives of patients and their families. That’s why they are studying ready-to-use liquid glucagon, but that’s just the beginning. Thet are also studying how their formulation technology can impact patients with other conditions. Xeris has a persistent drive to pursue advancement that have the potential to change lives – get to know them and see how their technology is unlocking the potential of today’s medicines at www.xerispharma.com.
Friends of CWD
Every day more than 4,000 people are newly diagnosed with diabetes in America. Nearly 115 million Americans have diabetes or prediabetes and are striving to manage their lives while living with the disease. The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For nearly 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Information is available in English and Spanish. Join the fight with us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).
Beta Bionics, Inc., is a Massachusetts public benefit corporation committed to commercializing and disseminating the iLet®, a bionic pancreas for people living with T1D. Our stated benefit mission is (1) to provide a turnkey solution for safe and effective autonomous glycemic control, (2) to bring this technology to as many people with T1D as possible, (3) to continue to innovate and to offer the latest advances, and (4) to act in the best possible interest of the T1D community. As a benefit corporation founded by parents of children with T1D, Beta Bionics, unlike any other medical technology company, is protected under Massachusetts law to prioritize its benefit mission and place the best interests of the T1D community ahead of all other considerations. Beta Bionics is pleased to be a sponsor of Friends for Life. To learn more about Beta Bionics, the iLet, and our public benefit mission, visit us at www.betabionics.org and @BetaBionics on social media.
Founded in February 2015, Beyond Type 1 created and funds a portfolio of programs, technologies and innovations that those living with type 1 diabetes need to manage, live and thrive. Our goal is to highlight the brilliance of those fighting this disease every day while always working toward ensuring a cure is on its way. By establishing a supportive community via powerful social media, people are connected on a global scale in a new way. Our Instagram campaign “Living Beyond,” showcases the age, range and variance of those living their best life with T1D, and our website and social media platforms provide education and support. High profile collaborations and carefully curated special events will provide education and awareness, affording a greater capacity for strategic fundraising. Because our Founders + Founding Friends pay all operational and fundraising expenses, 100% of every dollar raised directly supports the most promising global efforts and programs working to educate, advocate and cure type 1 diabetes. We aim to be provocative, inclusive and disruptive: putting a face on this disease, clearing up misunderstandings about who is affected by T1D and eradicating the stigma that comes from living with a chronic disease. We recognize there is a different narrative to be told: that of a strong empowered community living a powerful life beyond the diagnosis. We also recognize a future free of T1D is possible and we are here to make certain that future materializes. We are here to disrupt diabetes.
One of the first sponsors of Children with Diabetes in their very first year, the Diabetes Research Institute and Foundation are proud to be a part of this important educational and fun event for those affected by diabetes. The mission of the Diabetes Research Institute Foundation is to provide the Diabetes Research Institute with the funding necessary to cure diabetes now. The Diabetes Research Institute, a Center of Excellence at the University of Miami Miller School of Medicine, leads the world in cure-focused research. As the largest and most comprehensive research center dedicated to curing diabetes, the DRI is aggressively working to develop a biological cure by restoring natural insulin production. Researchers have already shown that diabetes can be reversed through islet transplantation, with some study patients living insulin free for more than a decade. The Institute is now building upon these promising outcomes by developing a DRI BioHub, an integrated “mini organ” that mimics that native pancreas, containing thousands of insulin-producing cells that sense blood sugar levels and produce the precise amount of insulin needed in real time. The Diabetes Research Institute and Foundation were created for one reason – to cure diabetes – which is and will continue to be its singular focus until that goal is reached. For the millions of children and adults affected by diabetes, the Diabetes Research Institute is the best hope for a cure. For more information, please visit www.DiabetesResearch.org or call 800-321-3437.
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.
With a vision to create a world without limits for people with diabetes, LifeScan is a world leader in blood glucose monitoring – globally more than 20 million people depend on OneTouch brand products to help them manage their diabetes. For over 35 years, LifeScan has had an unwavering commitment to improving the quality of life for people with diabetes by developing products defined by simplicity, accuracy, and trust. For more information, visit www.LifeScan.com and www.OneTouch.com.
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes, and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the company’s first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut. The company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Senseonics is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Our CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone. In the U.S., the Eversense System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider.
T1D Exchange is a nonprofit, research organization dedicated to accelerating therapies and improving care for people affected by type 1 diabetes. T1D Exchange actively supports discovery and innovation through its biobank and patient data. At the same time, the organization understands that evidence gathered in the “real world” can help bridge the gap between discovery in research settings and impact in people’s lives.
T1D Exchange model uses cutting-edge tools, research methods, and a robust IT platform to gather evidence from the real-world and clinical experiences of people living with type 1 diabetes. The goal is to connect biological samples, medical data, and patient insights to all stages of research and development, expediting the development of therapies and better care for everyone affected by type 1 diabetes.